Deal supported by Xplico

PharmaMar and Boryung Pharm sign a licensing agreement for Aplidin® (plitidepsin) in Korea.

By |October, 2016|Categories: Deal flow|0 Comments

Deal supported by Xplico

Nuevolution Announces Strategic Collaboration with Amgen in Oncology and Neuroscience.

By |October, 2016|Categories: Deal flow|0 Comments

Deal supported by Xplico

Sarepta Therapeutics and Summit Enter Into Exclusive License and Collaboration Agreement for European Rights to Summit’s Utrophin Modulator Pipeline for the Treatment of Duchenne Muscular Dystrophy.

By |October, 2016|Categories: Deal flow|0 Comments

Deal supported by Xplico

TRACON Pharmaceuticals Announces a Strategic Licensing Collaboration for Two Janssen Oncology Assets and a $5 Million Equity Investment from Johnson & Johnson Innovation – JJDC, Inc.

By |October, 2016|Categories: Deal flow|0 Comments

Spin-out supported by Xplico

4SC sells immunology portfolio to Immunic

By |September, 2016|Categories: Deal flow|0 Comments

Deal supported by Xplico

LEO Pharma enters biologics through strategic partnership with AstraZeneca.

By |July, 2016|Categories: Deal flow|0 Comments

Funding round supported by Xplico

AFFiRiS AG successfully raises €10m equity financing

By |June, 2016|Categories: Deal flow|0 Comments

Acquisition supported by Xplico

Targovax and Oncos Therapeutics join forces to create a Nordic leader within immuno-oncology.

By |June, 2016|Categories: Deal flow|0 Comments

Deal supported by Xplico

4SC enters into licensing and development partnership with Link Health for the cancer compound 4SC 205 in China.

By |May, 2016|Categories: Deal flow|0 Comments

Deal supported by Xplico

PharmaMar and Specialised Therapeutics Asia sign licensing and marketing agreement for APLIDIN® (plitidepsin) covering several Asian countries.

By |February, 2016|Categories: Deal flow|0 Comments